Eqis Capital Management Inc. increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 25.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,530 shares of the company’s stock after acquiring an additional 4,928 shares during the quarter. Eqis Capital Management Inc.’s holdings in AbbVie were worth $1,779,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Abner Herrman & Brock LLC lifted its stake in AbbVie by 0.3% in the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock valued at $456,000 after buying an additional 18 shares during the period. Ledyard National Bank lifted its stake in AbbVie by 7.8% in the second quarter. Ledyard National Bank now owns 19,832 shares of the company’s stock valued at $1,438,000 after buying an additional 1,439 shares during the period. Mn Services Vermogensbeheer B.V. lifted its stake in AbbVie by 501.2% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 260,590 shares of the company’s stock valued at $18,895,000 after buying an additional 217,244 shares during the period. Mascoma Wealth Management LLC lifted its stake in AbbVie by 1,589.5% in the second quarter. Mascoma Wealth Management LLC now owns 7,738 shares of the company’s stock valued at $561,000 after buying an additional 7,280 shares during the period. Finally, Franklin Street Advisors Inc. NC lifted its stake in AbbVie by 12.5% in the second quarter. Franklin Street Advisors Inc. NC now owns 215,187 shares of the company’s stock valued at $15,603,000 after buying an additional 23,908 shares during the period. 68.26% of the stock is currently owned by hedge funds and other institutional investors.

In related news, VP Robert A. Michael sold 6,699 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $88.00, for a total transaction of $589,512.00. Following the transaction, the vice president now directly owns 10,007 shares of the company’s stock, valued at approximately $880,616. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the transaction, the senior vice president now directly owns 93,099 shares in the company, valued at $7,915,276.98. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 379,890 shares of company stock worth $27,187,817. 0.23% of the stock is owned by company insiders.

AbbVie Inc. (NYSE ABBV) traded up 0.34% on Friday, hitting $90.49. The company had a trading volume of 3,462,155 shares. AbbVie Inc. has a one year low of $55.06 and a one year high of $91.33. The stock’s 50-day moving average price is $82.25 and its 200 day moving average price is $71.95. The company has a market capitalization of $144.25 billion, a P/E ratio of 22.26 and a beta of 1.51.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.02. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The business had revenue of $6.94 billion for the quarter, compared to the consensus estimate of $6.93 billion. During the same period in the prior year, the business earned $1.26 EPS. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. On average, analysts expect that AbbVie Inc. will post $5.52 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be paid a dividend of $0.64 per share. This represents a $2.56 dividend on an annualized basis and a yield of 2.83%. The ex-dividend date is Thursday, October 12th. AbbVie’s dividend payout ratio (DPR) is currently 62.90%.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/08/eqis-capital-management-inc-raises-stake-in-abbvie-inc-abbv.html.

Several equities analysts have weighed in on the company. Barclays PLC reissued a “hold” rating and issued a $68.00 target price on shares of AbbVie in a research note on Thursday, September 28th. Evercore ISI reissued an “outperform” rating and issued a $100.00 target price (up previously from $95.00) on shares of AbbVie in a research note on Saturday, September 30th. Piper Jaffray Companies reissued a “buy” rating and issued a $85.00 target price on shares of AbbVie in a research note on Thursday, August 3rd. BMO Capital Markets reissued a “hold” rating and issued a $66.00 target price on shares of AbbVie in a research note on Thursday, September 28th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $107.00 target price on shares of AbbVie in a research note on Thursday, September 28th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. AbbVie presently has a consensus rating of “Buy” and a consensus target price of $89.90.

AbbVie Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.